logo

PFE

Pfizer·NYSE
--
--(--)
--
--(--)

PFE fundamentals

Pfizer (PFE) released its earnings on Feb 3, 2026: revenue was 17.56B (YoY -1.16%), beat estimates; EPS was 0.66 (YoY +4.76%), beat estimates.
Revenue / YoY
17.56B
-1.16%
EPS / YoY
0.66
+4.76%
Report date
Feb 3, 2026
PFE Earnings Call Summary for Q4,2025
  • Obesity Portfolio Breakthrough: VESPER-3 delivers 10-12% weight loss at week 28 with monthly dosing, positioning '3944 as best-in-class. Phase III studies target 16%+ weight loss.
  • AI-Driven Productivity: 1,200+ GPUs deployed across Pfizer, enabling 20%+ R&D efficiency gains and 5% cost control in 2025.
  • Lyme Disease Vaccine Momentum: Phase III VALOR trial expected to read out H1 2026, addressing 400,000 U.S. and 132,000 European patients annually.
EPS
Revenue

Revenue & Expenses

PFE has released its 2025 Q4 earnings report, with revenue of 17.56B, reflecting a YoY change of -1.16%, and net profit of -1.64B, showing a YoY change of -492.34%. The Sankey diagram below clearly presents PFE's revenue sources and cost distribution.

Key Indicators

Pfizer (PFE) key financial stats and ratios, covering profitability, financial health, and leverage.
Pfizer (PFE)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Pfizer (PFE)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Pfizer (PFE)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Pfizer (PFE) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Pfizer (PFE) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield